BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 21490451)

  • 41. Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: a 15-year experience at a single institute.
    Cho BC; Jeung HC; Choi HJ; Rha SY; Hyung WJ; Cheong JH; Noh SH; Chung HC
    J Surg Oncol; 2007 May; 95(6):461-8. PubMed ID: 17192913
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neoadjuvant chemotherapy, radical resection with intraoperative radiation therapy (IORT): improved treatment for gastric adenocarcinoma.
    Weese JL; Harbison SP; Stiller GD; Henry DH; Fisher SA
    Surgery; 2000 Oct; 128(4):564-71. PubMed ID: 11015089
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas.
    Brücher BL; Becker K; Lordick F; Fink U; Sarbia M; Stein H; Busch R; Zimmermann F; Molls M; Höfler H; Siewert JR
    Cancer; 2006 May; 106(10):2119-27. PubMed ID: 16607651
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Assessment of tumor regression of esophageal adenocarcinomas after neoadjuvant chemotherapy: comparison of 2 commonly used scoring approaches.
    Karamitopoulou E; Thies S; Zlobec I; Ott K; Feith M; Slotta-Huspenina J; Lordick F; Becker K; Langer R
    Am J Surg Pathol; 2014 Nov; 38(11):1551-6. PubMed ID: 25140894
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multivariate prognostic study on node-positive gastric cancer: is tumor size a prognostic indicator?
    Liu Y; Chen XH; Meng XH; Liu CF; Zhao LL; Han JW; Zhuang LW
    Hepatogastroenterology; 2012; 59(114):623-6. PubMed ID: 22024039
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic role of lymphatic vessel invasion in early gastric cancer: a retrospective study of 188 cases.
    Liu C; Zhang R; Lu Y; Li H; Lu P; Yao F; Jin F; Xu H; Wang S; Chen J
    Surg Oncol; 2010 Mar; 19(1):4-10. PubMed ID: 19042124
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tumor regression grade of urothelial bladder cancer after neoadjuvant chemotherapy: a novel and successful strategy to predict survival.
    Fleischmann A; Thalmann GN; Perren A; Seiler R
    Am J Surg Pathol; 2014 Mar; 38(3):325-32. PubMed ID: 24525502
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tumor volume as a prognostic factor was superior to the seventh edition of the pT classification in resectable gastric cancer.
    Jiang N; Deng JY; Ding XW; Liu Y; Liang H
    Eur J Surg Oncol; 2015 Mar; 41(3):315-22. PubMed ID: 25601610
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute.
    Moon YW; Jeung HC; Rha SY; Yoo NC; Roh JK; Noh SH; Kim BS; Chung HC
    Ann Surg Oncol; 2007 Oct; 14(10):2730-7. PubMed ID: 17632757
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Significant prognostic factors in patients with early gastric cancer.
    Yokota T; Kunii Y; Teshima S; Yamada Y; Saito T; Takahashi M; Kikuchi S; Yamauchi H
    Int Surg; 2000; 85(4):286-90. PubMed ID: 11589593
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pre-adjuvant chemotherapy leukocyte count may predict the outcome for advanced gastric cancer after radical resection.
    Pei D; Zhu F; Chen X; Qian J; He S; Qian Y; Shen H; Liu Y; Xu J; Shu Y
    Biomed Pharmacother; 2014 Mar; 68(2):213-7. PubMed ID: 24581723
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.
    Di Costanzo F; Gasperoni S; Manzione L; Bisagni G; Labianca R; Bravi S; Cortesi E; Carlini P; Bracci R; Tomao S; Messerini L; Arcangeli A; Torri V; Bilancia D; Floriani I; Tonato M; ; Dinota A; Strafiuso G; Corgna E; Porrozzi S; Boni C; Rondini E; Giunta A; Monzio Compagnoni B; Biagioni F; Cesari M; Fornarini G; Nelli F; Carboni M; Cognetti F; Enzo MR; Piga A; Romiti A; Olivetti A; Masoni L; De Stefanis M; Dalla Mola A; Camera S; Recchia F; De Filippis S; Scipioni L; Zironi S; Luppi G; Italia M; Banducci S; Pisani Leretti A; Massidda B; Ionta MT; Nicolosi A; Canaletti R; Biscottini B; Grigniani F; Di Costanzo F; Rovei R; Croce E; Carroccio R; Gilli G; Cavalli C; Olgiati A; Pandolfi U; Rossetti R; Natalini G; Foa P; Oldani S; Bruno L; Cascinu S; Catalano G; Catalano V; Lungarotti F; Farris A; Sarobba MG; Trignano M; Muscogiuri A; Francavilla F; Figoli F; Leoni M; Papiani G; Orselli G; Antimi M; Bellini V; Cabassi A; Contu A; Pazzola A; Frignano M; Lastraioli E; Saggese M; Bianchini D; Antonuzzo L; Mela M; Camisa R
    J Natl Cancer Inst; 2008 Mar; 100(6):388-98. PubMed ID: 18334706
    [TBL] [Abstract][Full Text] [Related]  

  • 53. AKR1B10, a good prognostic indicator in gastric cancer.
    Yao HB; Xu Y; Chen LG; Guan TP; Ma YY; He XJ; Xia YJ; Tao HQ; Shao QS
    Eur J Surg Oncol; 2014 Mar; 40(3):318-24. PubMed ID: 24406159
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Factors predicting prognosis and recurrence in patients with esophago-gastric adenocarcinoma and histopathological response with less than 10 % residual tumor.
    Ott K; Blank S; Becker K; Langer R; Weichert W; Roth W; Sisic L; Stange A; Jäger D; Büchler M; Siewert JR; Lordick F
    Langenbecks Arch Surg; 2013 Feb; 398(2):239-49. PubMed ID: 23269519
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The prognostic value of lymph node metastases and tumour regression grade in rectal cancer patients treated with long-course preoperative chemoradiotherapy.
    Lindebjerg J; Spindler KL; Ploen J; Jakobsen A
    Colorectal Dis; 2009 Mar; 11(3):264-9. PubMed ID: 18573119
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Survival analysis after surgical treatment of gastric cancer: review of 121 cases.
    Nazli O; Derici H; Tansug T; Yaman I; Bozdag AD; Isgüder AS; Bölükbasi H
    Hepatogastroenterology; 2007 Mar; 54(74):625-9. PubMed ID: 17523337
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Morphologic response evaluation of neoadjuvant chemotherapy of gastric carcinoma].
    Becker K; Mueller J; Fink U; Busch R; Siewert JR; Höfler H
    Verh Dtsch Ges Pathol; 2000; 84():164-74. PubMed ID: 11217437
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A phase II study of neoadjuvant and adjuvant chemotherapy with 5-fluorodeoxyuridine, leucovorin, oxaliplatin and docetaxel in the treatment of previously untreated advanced esophageal adenocarcinoma.
    Solomon N; Mezentsev D; Reis I; Lima M; Rios J; Avisar E; Franceschi D; Livingstone A; Podolsky L; Ardalan B
    Jpn J Clin Oncol; 2011 Apr; 41(4):469-76. PubMed ID: 21258083
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Correlation of the histological effects and survival after neoadjuvant chemotherapy on gastric cancer patients.
    Yonemura Y; Kinoshita K; Fujimura T; Fushida S; Sawa T; Matsuki N; Tanaka S; Kamata T; Takashima T; Miyazaki I
    Hepatogastroenterology; 1996; 43(11):1260-72. PubMed ID: 8908561
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Efficacy of neoadjuvant chemotherpy in patients with locally advanced gastric cancer].
    Wang Y; Liu TS; Zhuang RY; Cui YH; Wang ZM; Yu YY; Hou J; Sun YH; Shen KT; Shen ZB
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Feb; 16(2):166-9. PubMed ID: 23446480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.